Ery

Hauptinformation

  • Handelsname:
  • Ery - Set - Lösung zur Verdünnung von Erythrozytenkonzentrat
  • Einheiten im Paket:
  • 20 x 100 ml, Laufzeit: 12 Monate
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • für die Allgemeinheit:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie das Informationsblatt für die Öffentlichkeit.

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Ery - Set  - Lösung zur Verdünnung von Erythrozytenkonzentrat
    Österreich
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiebereich:
  • Lösungs- und Verdünnungsm

Weitere Informationen

Status

  • Quelle:
  • AGES
  • Zulassungsnummer:
  • 1-19347
  • Letzte Änderung:
  • 07-11-2016

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

22-6-2018

Dringende Sicherheitsinformation zu Geratherm Patient Warming System UniqueTemp° Recovery, Recovery Set 1 von Geratherm Medical AG

Dringende Sicherheitsinformation zu Geratherm Patient Warming System UniqueTemp° Recovery, Recovery Set 1 von Geratherm Medical AG

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

14-6-2018

ANSES consolidates its presence in Boulogne-sur-Mer!

ANSES consolidates its presence in Boulogne-sur-Mer!

Centrally located in the port of Boulogne-sur-Mer, the Laboratory for Food Safety's site specialising in fishery and aquaculture products is expanding! This extension, financed jointly by the Hauts-de-France Region and the local community, underlines ANSES's scientific investment in Boulogne-sur-Mer and is fully consistent with regional research dynamics for the quality and safety of aquatic products.

France - Agence Nationale du Médicament Vétérinaire

13-6-2018

Carmen Jewellery Inc. recalls Kenneth Cole-branded men's watches

Carmen Jewellery Inc. recalls Kenneth Cole-branded men's watches

The clear domed crystal glass on the watch face may detach or shatter, posing a physical or laceration hazard.

Health Canada

4-6-2018

Medical Devices that Treat Obesity: What to Know

Medical Devices that Treat Obesity: What to Know

Obesity has been linked to many health problems, including heart disease, diabetes, and high blood pressure. Treatments for obesity range from healthy eating and exercise to prescription medicine and surgery. In recent years, FDA-regulated medical devices have also played a treatment role. Learn about approved products.

FDA - U.S. Food and Drug Administration

17-5-2018

The Michaels Companies, Inc. recalls Creatology Pottery Wheel Kit and Creatology Spin Art Kit

The Michaels Companies, Inc. recalls Creatology Pottery Wheel Kit and Creatology Spin Art Kit

Internal wiring within the product may overheat posing a risk of burns or fire.

Health Canada

19-9-2018

If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery.

More on filing a flood insurance claim:  http://fema.

If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery. More on filing a flood insurance claim: http://fema.

If your home was damaged or if you had flood loss due to #Florence, start the recovery process by filing your homeowner’s and flood insurance claims. Insurance is the most effective tool for recovery. More on filing a flood insurance claim: http://fema.gov/nfip-file-your-claim … pic.twitter.com/lv5Na8Zw8c

FDA - U.S. Food and Drug Administration

19-9-2018

Every disaster is different & each person has unique needs after #Florence. A variety of resources may be available to help with recovery:

Call 2-1-1 to connect with local sources of help.
 http://DisasterAssistance.gov  connects you with federal or volu

Every disaster is different & each person has unique needs after #Florence. A variety of resources may be available to help with recovery: Call 2-1-1 to connect with local sources of help. http://DisasterAssistance.gov  connects you with federal or volu

Every disaster is different & each person has unique needs after #Florence. A variety of resources may be available to help with recovery: Call 2-1-1 to connect with local sources of help. http://DisasterAssistance.gov  connects you with federal or voluntary organization resources. pic.twitter.com/UYuxr0yvF0

FDA - U.S. Food and Drug Administration

22-7-2018

#FDA thoroughly evaluates risks and the potential for user error before a device is cleared or approved for marketing. But we know that not everything can be revealed and known about a device before it reaches the market

#FDA thoroughly evaluates risks and the potential for user error before a device is cleared or approved for marketing. But we know that not everything can be revealed and known about a device before it reaches the market

#FDA thoroughly evaluates risks and the potential for user error before a device is cleared or approved for marketing. But we know that not everything can be revealed and known about a device before it reaches the market

FDA - U.S. Food and Drug Administration

16-7-2018

Loceryl® Nagellack gegen Nagelpilz

Rote - Liste

26-6-2018

Cost recovery implementation statement

Cost recovery implementation statement

Updated to include new fees and charges effective 1 July 2018

Therapeutic Goods Administration - Australia

12-6-2018

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt) - Transfer of orphan designation - Commission Decision (2018)3797 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/16/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt) - Transfer of orphan designation - Commission Decision (2018)3798 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/166/12/T/01

Europe -DG Health and Food Safety